Search Browse Earnings

Aprea Therapeutics, Inc.

Nasdaq:APRE

Pharmaceutical Preparations·DOYLESTOWN, PA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Aprea Therapeutics, Inc. — SlamSEC

Revenue

—

Adj. EBITDA

-$15.5M

FY 2024

Net Income

-$14.3M

FY 2024

EPS (Diluted)

-$3.95

FY 2024

Stock Price

$0.90

-2.3%

2026-03-06

52W Range

$0.55 – $2.76

P/E Ratio

-0.2x

Market Cap

$5.7M

Cash

$21.6M

FY 2024

Total Debt

—

Net Cash

$21.6M

Enterprise Value

-$15.9M

Debt / EBITDA

1.4x

FY 2024

EV / EBITDA

1.0x

Employees

—

CEO

Gilad Oren

CFO

Hamill John P.